Business
Moderna’s Cancer Vaccine Hopes Diminish
Investors' high expectations for Moderna's experimental cancer vaccine have cooled, as the drugmaker faces challenges in Phase 3 data.
Coverage timeline — 1 article
MarketWatch
Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.
2026-10-26 13:50 UTC